How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Pharma and Healthcare · Forecast 2027–2033
Life Science Reagent Market
- By Product Type: Enzymes, Antibodies, Nucleic Acids, Buffers and Solutions, Kits and Assay Reagents
- By Application: Genomics, Proteomics, Drug Discovery, Diagnostics, Cell Biology
- By End User: Pharmaceutical and Biotechnology Companies, Academic and Research Institutes, Clinical Laboratories, Contract Research Organizations (CROs), Biopharmaceutical Manufacturing
- By Technology: Polymerase Chain Reaction (PCR), Western Blotting, Flow Cytometry, ELISA, Next-Generation Sequencing (NGS)
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Projected to reach $X,XXX.XM by 2033 on sustained demand. Market Outlook →
- 03 Growth - X.XX% CAGR across 2027–2033, with the full year-by-year model inside. Market Outlook →
- 04 Leading segment - Enzymes leads By Product Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 281 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.170 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.178 →
Full report · locked preview
Everything inside the Life Science Reagent Market report
A complete, evidence-based study - 11 chapters and 118 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Product Type 5
Application 5
End User 5
Technology 5
Companies profiled
Thermo Fisher Scientific
Merck KGaA (MilliporeSigma)
Danaher Corporation (Cytiva)
Bio-Rad Laboratories
Agilent Technologies
PerkinElmer
QIAGEN
Promega Corporation
New England Biolabs
Takara Bio
GE Healthcare Life Sciences
Santa Cruz Biotechnology
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Thermo Fisher Scientific
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Merck KGaA (MilliporeSigma)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Danaher Corporation (Cytiva)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Bio-Rad Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Agilent Technologies
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →PerkinElmer
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →QIAGEN
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Promega Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →New England Biolabs
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Takara Bio
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →GE Healthcare Life Sciences
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Santa Cruz Biotechnology
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Abcam
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Lonza Group
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Sartorius AG
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →
Global · 2025–2033
$10,608M by 2033 · 9.4% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Enzymes31.7
- Antibodies23.0
- Nucleic Acids19.4
- Buffers and Solutions14.7
- Kits and Assay Reagents11.2
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,708M → $3,115M · 7.8%
Europe$1,190M → $2,693M · 10.7%
Asia Pacific$1,087M → $2,455M · 10.7%
Latin America$672.7M → $1,299M · 8.6%
Middle East and Africa$517.5M → $1,139M · 10.4%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →9.352026
9.352027
9.362028
9.372029
9.392030
9.412031
9.412032
9.432033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Thermo Fisher Scientific16.6
- Merck KGaA (MilliporeSigma)9.8
- Danaher Corporation (Cytiva)12.2
- Bio-Rad Laboratories11.7
- Agilent Technologies12.7
- PerkinElmer9.0
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Product Type35.5%
Application29.3%
End User23.7%
Technology11.5%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America29.1
- Europe25.2
- Asia Pacific22.9
- Latin America12.1
- Middle East and Africa10.6
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Thermo Fisher Scientific | 79 | 85 | 90 | 96 | 86 | 95 | 89 |
| Merck KGaA (MilliporeSigma) | 78 | 85 | 90 | 92 | 82 | 76 | 84 |
| Danaher Corporation (Cytiva) | 84 | 77 | 83 | 86 | 65 | 72 | 78 |
| Bio-Rad Laboratories | 66 | 57 | 78 | 80 | 58 | 65 | 67 |
| Agilent Technologies | 75 | 64 | 71 | 63 | 70 | 76 | 70 |
| PerkinElmer | 71 | 51 | 50 | 54 | 49 | 56 | 55 |
| QIAGEN | 52 | 58 | 60 | 52 | 55 | 48 | 54 |
| Promega Corporation | 58 | 53 | 53 | 59 | 40 | 36 | 50 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Thermo Fisher Scientific
- Merck KGaA (MilliporeSigma)
- Danaher Corporation (Cytiva)
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific | ◐ | ◐ | ✓ | ✓ | ✓ | ✓ |
| Merck KGaA (MilliporeSigma) | ✓ | ✓ | ✓ | ✓ | ◐ | ◐ |
| Danaher Corporation (Cytiva) | ◐ | ◐ | ◐ | ✓ | − | − |
| Bio-Rad Laboratories | ◐ | ◐ | ✓ | ✓ | ◐ | ◐ |
| Agilent Technologies | ◐ | ◐ | − | ◐ | − | ◐ |
| PerkinElmer | ◐ | ◐ | ◐ | ◐ | ◐ | − |
| QIAGEN | ◐ | − | − | − | − | − |
| Promega Corporation | − | ◐ | − | ◐ | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Thermo Fisher Scientific89
2Merck KGaA (MilliporeSigma)84
3Danaher Corporation (Cytiva)78
4Agilent Technologies70
5Bio-Rad Laboratories67
6PerkinElmer55
7QIAGEN54
8Promega Corporation50
Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Thermo Fisher ScientificMerck KGaA (MilliporeSigma)Danaher Corporation (Cytiva)
Challenger2
Strong scale, closing on the leaders.
Bio-Rad LaboratoriesAgilent Technologies
Niche3
Specialists in a single segment or region.
PerkinElmerQIAGENPromega Corporation
Go-to-market strategy
Land Product Type in North America, then scale across Life Science Reagent Market — a $545M beachhead inside a $8.73B market.
Beachhead (SOM)$545Mobtainable near-term
Serviceable (SAM)$3.24Breachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion90 fit
Enzymes
Best fit — highest urgency & budget in Product Type.
Economic buyer78 fit
Antibodies
Strong fit — clear ROI and a fast path to value.
End user70 fit
Nucleic Acids
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Product Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Application & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales48%
Partner / channel28%
Digital / self-serve18%
Marketplaces7%
Positioning & messaging
§GTM 2 · p.194 →For Product Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Life Science Reagent Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified44%
Sales qualified20%
Evaluation13%
Closed-won6%
$9.4KCAC
$33KLTV
3.5:1LTV : CAC
< 3 moCAC payback
Investment thesis
Life Science Reagent Market is a high-growth opportunity — $5.24B by 2033, compounding at 10.4%.
TAM · 2025$2.38Btoday
TAM · 2033$5.24Bforecast
CAGR10.4%2027–2033
Cumulative$32.8Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$5.24BTotal addressable market
SAM$2.11BServiceable available market
SOM$370MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →10.4% CAGR
Demand compounds through 2033, outpacing GDP across Product Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Product Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$5.24BLarge & growingTAM by 2033 at 10.4% CAGR
$2.11BServiceable nowreachable with today’s model
$370MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.09BBear6.7% CAGR
$5.24BBase10.4% CAGR
$6.71BBull13.7% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Application optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Life Science Reagent Market — a $6.26B market by 2033. Plan: grow share from 8.0% to 17.0%.
Market size · 2033$6.26Btotal addressable
Market CAGR9.8%2027–2033
Target share17.0%from 8.0% today
Revenue ambition$1.06Bby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.0% | 17.0% | Ahead |
| Revenue | $485M | $1.06B | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | Behind |
| Gross margin | 34.7% | 40.3% | At risk |
| Customer retention | 86.9% | 94.0% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Product Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Application capability
A defensible second engine — invest in Application to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Product Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Application
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $138M capacity & capability investment
- Greenlight bolt-on M&A in Application
- Authorise North America expansion plan
- Fund R&D program for Product Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossAt risk
- Input-cost & supply riskOn track
- Regulatory / policy changeAhead
- Execution & talentAt risk
Sales deck · value proposition
Win the Life Science Reagent Market conversation — a $5.08B market you can size, segment and defend in minutes.
Market size · 2033$5.08Btotal opportunity
Growth6.0%CAGR to 2033
Addressable buyers1,114+accounts in scope
Typical ROI4.3×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Product Type
Goal Grow share in Product Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →4.3×return on cost, year one
< 3 mopayback period
$94K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Thermo Fisher ScientificMerck KGaA (MilliporeSigma)Danaher Corporation (Cytiva)Bio-Rad LaboratoriesAgilent TechnologiesPerkinElmerQIAGENPromega Corporation+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Life Science Reagent Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Life Science Reagent Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Pharma and Healthcare · scroll →H2-Receptor Antagonists Market
Market size, share, segmentation and regional forecast.
$1.7B by 2032 · 7.42% CAGR
View reportArtificial Blood Substitutes Market
Market size, share, segmentation and regional forecast.
$13.4B by 2031 · 10.41% CAGR
View reportQuinolones Market
Market size, share, segmentation and regional forecast.
$12.1B by 2031 · 9.90% CAGR
View reportHypothyroidism Drugs Market
Market size, share, segmentation and regional forecast.
$14.6B by 2033 · 3.70% CAGR
View reportQuinestrol (CAS 57-63-6) Market
Market size, share, segmentation and regional forecast.
$14.8B by 2032 · 6.27% CAGR
View reportSisomicin Sulfate (CAS 53179-09-2) Market
Market size, share, segmentation and regional forecast.
$12.4B by 2033 · 8.91% CAGR
View reportRifampin Market
Market size, share, segmentation and regional forecast.
$13.6B by 2031 · 5.32% CAGR
View reportParkinson's Disease Treatments Market
Market size, share, segmentation and regional forecast.
$6.7B by 2031 · 3.78% CAGR
View reportNasal Polyposis Drug Market
Market size, share, segmentation and regional forecast.
$7.6B by 2031 · 3.71% CAGR
View reportHepatic Encephalopathy Drug Market
Market size, share, segmentation and regional forecast.
$3.6B by 2033 · 10.43% CAGR
View reportUnilateral Cochlear Implants Market
Market size, share, segmentation and regional forecast.
$12.9B by 2031 · 4.05% CAGR
View reportInfectious Disease Diagnostics Market
Market size, share, segmentation and regional forecast.
$7.9B by 2031 · 6.12% CAGR
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report ships as a formatted PDF, a fully editable XLSX containing all underlying data tables, and a presentation-ready PPT deck - so you can re-chart, re-model, or drop any figure straight into your own deck.